Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study

Abstract

The results of this pilot study suggest that solifenacin might affect morphometric properties of the prostate, decreasing total prostate and adenoma volume, as well as vascularity. A molecular effect of antimuscarinics on the prostate, in parallel with their expected bladder effect, warrants further investigation.

Relationship between frailty and lower urinary tract symptoms among community‐dwelling adults

“…Lower urinary tract symptoms (LUTS) are among the most common urologic conditions in the older population . As the incidence of LUTS and frailty increases with age, the concept of frailty has been recognized as a key factor in older individuals with LUTS . However, only a few studies have evaluated the influence of frailty on LUTS .…”

Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms

“…The non-DO monotherapy subgroup showed comparable efficacy to the non-DO combination treatment subgroup in improving nocturia episodes (P = 0.599). In the analysis of unstratified data, nocturia episodes were reduced in both treatment arms, with near-statistical significance for the combination treatment (monotherapy, -1.5 vs. combination, -2.0, P = 0.057) [14]. Fig.…”

“…The non-DO monotherapy subgroup showed comparable efficacy to the non-DO combination treatment subgroup in terms of improvements in urgency episodes (P = 0.126). In the initial study, both treatment groups showed improvements in urgency episodes as compared to baseline (monotherapy, -3.0 vs. combination, -3.5; P < 0.001), and the intergroup comparison did not reveal any significant differences [14]. Nocturia also improved in men with DO who received combination treatment as compared to the DO monotherapy subgroup (P = 0.018), to the non-DO combination treatment subgroup (P = 0.03), and to the non-DO monotherapy subgroup (P = 0.037).…”

“…This is a post hoc analysis of a prospective, randomized study conducted at 2 centers between October 2013 and June 2015. The initial study was designed to evaluate changes in the morphometric parameters of the prostate following α-blocker monotherapy or combination of an α-blocker with an anticholinergic [14]. The study was approved by the Institutional Review Board and the Ethics Committees of both sites and followed Good Clinical Practice guidelines.…”

“…We hypothesized that DO may be a predictor of responsiveness to therapy and clinical outcomes in men with benign prostatic enlargement (BPE) and OAB. To examine this hypothesis, we conducted a posthoc analysis of our pilot randomized trial, assessing the efficacy of tamsulosin monotherapy versus combination with solifenacin in men with OAB due to BPE [14].…”